Yumanity Therapeutics

790 Memorial Drive, Suite 2C
Cambridge
Massachusetts
02139
United States

Tel: 617-409-5300

About Yumanity Therapeutics

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Despite the estimated patient population of 50 million people worldwide, this remains an area of tremendous unmet medical need with no approved disease-modifying therapies or cures. Yumanity is working to identify and develop new, disease-modifying therapies that address illnesses such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). The company’s approach concentrates on correcting the cellular pathologies driven by misfolded proteins and the altered biology and phenotypes driving these diseases.

8 articles with Yumanity Therapeutics

BioSpace Movers and Shakers, July 12

7/12/2019

Biotech and pharma companies strengthen their leadership teams with new appointments.
Yumanity Therapeutics Appoints Richard Peters, M.D., Ph.D., as Chief Executive Officer

7/10/2019

Yumanity Therapeutics, a company focused on discovering and developing transformative therapies to treat neurodegenerative diseases, today announced the appointment of accomplished physician, scientist, and industry veteran Richard Peters, M.D., Ph.D., as chief executive officer (CEO).
Yumanity Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference

5/23/2019

Yumanity Therapeutics announced that Tony Coles, M.D., chairman and chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5 at 2:30 p.m. EDT.
Yumanity Therapeutics Announces Publication of Paper in Cell Reports Detailing a Potential New Therapeutic Target for the Treatment of Parkinson’s Disease

12/4/2018

Results suggest inhibiting fatty acid desaturation by blocking the enzyme stearoyl-CoA desaturase (SCD) is a potential therapeutic approach to treating neurodegenerative diseases
Yumanity Therapeutics Announces First Clinical Candidate for the Potential Treatment of Parkinson’s Disease

9/5/2018

First-in-Human Trials Planned for the Fourth Quarter of 2019
Yumanity And The New York Stem Cell Foundation Research Institute Announce Discovery Collaboration

6/22/2016
Like Dimension Therapeutics, More Than Half of Yumanity's Employees are Women

2/12/2016
Startup Yumanity Closes on $45 Million, With Biogen and Sanofi-Genzyme BioVentures Joining In

2/10/2016